Monte Rosa Therapeutics (GLUE) Expected to Announce Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.2396) per share and revenue of $33.87 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $8.97 million for the quarter, compared to analyst estimates of $12.91 million. Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. On average, analysts expect Monte Rosa Therapeutics to post ($1.13) EPS for the current fiscal year and ($1.55) EPS for the next fiscal year.

Monte Rosa Therapeutics Trading Down 1.2%

Shares of GLUE stock opened at $10.63 on Tuesday. The company has a market cap of $906.88 million, a price-to-earnings ratio of -6.04 and a beta of 1.37. The stock has a 50 day simple moving average of $12.00 and a 200-day simple moving average of $17.36. Monte Rosa Therapeutics has a 12-month low of $9.68 and a 12-month high of $25.77.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Weiss Ratings lowered Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. Wells Fargo & Company cut their price objective on Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Raymond James Financial set a $25.00 target price on Monte Rosa Therapeutics in a report on Monday, October 5th. JPMorgan Chase & Co. decreased their target price on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Finally, Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of Monte Rosa Therapeutics in a research note on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing molecular glue degraders, a class of medicines designed to eliminate disease-causing proteins by directing them to the cell’s natural protein-degradation machinery. The company’s approach is intended to address targets that may be difficult to inhibit with conventional small-molecule drugs.

Monte Rosa uses its QuEEN platform to discover and optimize molecular glue degraders for diseases involving dysregulated immune responses and other biological pathways.